Lobo Yolanka, Templeman Rupert
Veracity Clinical Research, Brisbane, Queensland.
Dermatol Online J. 2020 Jul 15;26(7):13030/qt5tc7c9w7.
The use of imiquimod 5% cream, a topical immunomodulator for the treatment of lentigo maligna (LM) was first described in 2000. Subsequent studies have indicated that imiquimod might be an effective nonsurgical treatment in patients who refuse to have, or are ineligible for surgery because of comorbidities, tumor size, or risk of cosmetic disfigurement. Herein, we outline our experience with treating LM on the nose in an 88-year-old skin cancer patient with significant comorbidities. Given our patient's strong preference against surgical intervention, he was treated with topical imiquimod cream applied once daily for a total of 12 weeks. A two-week treatment holiday was required for severe nausea and vomiting, treated effectively with ondansetron wafers. There were no clinical or dermoscopic signs of LM recurrence 12 months posttreatment. Topical imiquimod is an effective alternative to excision in nonsurgical candidates.
5%咪喹莫特乳膏作为一种用于治疗恶性雀斑样痣（LM）的局部免疫调节剂，其应用最早于2000年被描述。随后的研究表明，对于因合并症、肿瘤大小或美容毁容风险而拒绝手术或不适合手术的患者，咪喹莫特可能是一种有效的非手术治疗方法。在此，我们概述了我们对一名患有严重合并症的88岁皮肤癌患者鼻部LM的治疗经验。鉴于我们的患者强烈反对手术干预，他接受了局部咪喹莫特乳膏治疗，每天涂抹一次，共12周。因严重恶心和呕吐需要两周的治疗假期，使用昂丹司琼片有效治疗。治疗后12个月，没有LM复发的临床或皮肤镜迹象。局部应用咪喹莫特是手术禁忌患者切除治疗的有效替代方法。
